Literature DB >> 33188394

SARS-CoV-2 Triggering Severe Acute Respiratory Distress Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in a 3-Year-Old Child With Down Syndrome.

Sarah Kim-Hellmuth1, Matthias Hermann2, Julia Eilenberger1, Julia Ley-Zaporozhan3, Marcus Fischer2, Fabian Hauck1, Christoph Klein1,4, Nikolaus Haas2, Matthias Kappler1, Johannes Huebner1,4, André Jakob2, Ulrich von Both1,4.   

Abstract

Down syndrome (DS) predisposes to severe immunologic reaction secondary to infectious triggers. Here, we report a pediatric DS patient with coronavirus disease 2019 (COVID-19) who developed a hyperinflammatory syndrome, severe acute respiratory distress syndrome, and secondary hemophagocytic lymphohistiocytosis requiring pediatric intensive care unit admission and treatment with steroids, intravenous immunoglobulin, and remdesivir. Investigations into genetic susceptibilities for COVID-19 and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-associated complications warrant systematic clinical and scientific studies. We report a pediatric Down syndrome patient with coronavirus disease 2019 (COVID-19) who developed secondary hemophagocytic lymphohistiocytosis requiring treatment with steroids, intravenous immunoglobulin, and remdesivir. Investigations into genetic susceptibilities for COVID-19-associated complications warrant systematic clinical and scientific studies.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Down syndrome; hyperinflammation; pediatrics; remdesivir; sHLH

Year:  2021        PMID: 33188394      PMCID: PMC7717321          DOI: 10.1093/jpids/piaa148

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  5 in total

1.  Clinical characteristics and comorbidities of COVID-19 in unvaccinated patients with Down syndrome: first year report in Brazil.

Authors:  Matheus Negri Boschiero; Camila Vantini Capasso Palamim; Fernando Augusto Lima Marson; Manoela Marques Ortega
Journal:  Hum Genet       Date:  2022-06-28       Impact factor: 5.881

2.  Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524.

Authors:  Daniela Krentz; Katharina Zenger; Martin Alberer; Sandra Felten; Michèle Bergmann; Roswitha Dorsch; Kaspar Matiasek; Laura Kolberg; Regina Hofmann-Lehmann; Marina L Meli; Andrea M Spiri; Jeannie Horak; Saskia Weber; Cora M Holicki; Martin H Groschup; Yury Zablotski; Eveline Lescrinier; Berthold Koletzko; Ulrich von Both; Katrin Hartmann
Journal:  Viruses       Date:  2021-11-05       Impact factor: 5.048

3.  A Case Report for Severe COVID-19 in a 9-Year-Old Child Treated with Remdesivir and Dexamethasone.

Authors:  Yoon Hee Jo; Yosub Hwang; Soo Han Choi
Journal:  J Korean Med Sci       Date:  2021-07-26       Impact factor: 2.153

4.  Weekly SARS-CoV-2 Sentinel Surveillance in Primary Schools, Kindergartens, and Nurseries, Germany, June‒November 2020.

Authors:  Martin Hoch; Sebastian Vogel; Laura Kolberg; Elisabeth Dick; Volker Fingerle; Ute Eberle; Nikolaus Ackermann; Andreas Sing; Johannes Huebner; Anita Rack-Hoch; Tilmann Schober; Ulrich von Both
Journal:  Emerg Infect Dis       Date:  2021-06-04       Impact factor: 6.883

5.  Ensuring global access to COVID-19 vaccines: deployment strategies for refugees and migrants must not be forgotten.

Authors:  Danilo Buonsenso; Ulrich von Both
Journal:  Infection       Date:  2021-05-28       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.